Salubris Pharmaceuticals streamlines governance, abolishes supervisory board

Shenzhen Salubris Pharmaceuticals announced the abolishment of its supervisory board, with its functions to be absorbed by the audit committee, effective upon shareholder approval. This decision, approved by the sixth board of directors and the sixth supervisory board on December 9, 2025, necessitated revisions to the company's Articles of Association and 31 other governance documents. These include updated regulations for shareholder meetings, board of directors' meetings, independent director operations, external guarantees, related party transactions, and financial management, all to be presented for shareholder review on December 25, 2025.

The proposed changes aim to streamline operations, enhance governance stability, and protect shareholder interests by aligning with the latest legal and regulatory requirements. The revisions ensure robust internal controls, information disclosure, and risk management, with specific procedures for handling financial derivatives, fundraising, and internal audit processes. The company will continue to operate under existing supervisory board mandates until the changes are formally approved by shareholders.